Aurobindo Pharma's subsidiary to invest over Rs300 crore in expanding biologics manufacturing facility

Aurobindo Vaccines to provide contract manufacturing services to international vaccine makers

September 02, 2022 8:17 IST | India Infoline News Service

Aurobindo Pharma said on Thursday that CuraTeQ Biologics, a fully owned subsidiary, aims to invest close to Rs300 crore in the capacity development of biologics production facilities.

According to a regulatory filing by Aurobindo Pharma, the board of directors of CuraTeQ Biologics Pvt Ltd approved the expansion of its operations by creating a second, larger-capacity mammalian cell culture production facility to accommodate future demands.

It said that the facility is probably going to be completely operational by FY26 and that the capital cost for scaling up capabilities is projected to be approximately Rs 300 crore. The board also authorized starting contract manufacturing operations (CMO) for biologicals in order to use capacity effectively.

As the market for global biologics contract manufacturing is increasing at a rate of 8–10%, this would improve business possibilities in the field, and CuraTeQ said it will actively seek out clients in the CMO sector.

The firm also announced that Auro Vaccines Pvt Ltd's board has authorized studying the possibility of providing contract manufacturing services to international vaccine developers in order to efficiently use its current manufacturing capacity. The company Auro Vaccines is in the business of creating and producing biological vaccines.

For feedback and suggestions, write to us at editorial@iifl.com

Invest wise with Expert advice



Open Demat Account

Invest wise with Expert advice

By continuing, I accept the Terms & Conditions and agree to receive updates on Whatsapp